Stay updated on Pembrolizumab for Metastatic Anal Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Anal Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic Anal Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no visible changes to study details or user-facing content.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 was added and the government funding notice along with Revision: v3.4.1 were removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a site-wide notice about the government funding lapse and NIH Clinical Center operating status with links for more information. Updated the page footer from Revision: v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a glossary option, updated metadata labels (Last Update Submitted that Met QC Criteria, Revision: v3.4.0), and adjusted capitalization (No FEAR Act data); these cosmetic changes do not affect core study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page revision stamp was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a dedicated Locations section with Massachusetts and Washington listings; removed the HHS Vulnerability Disclosure link; updated page revision to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab for Metastatic Anal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Anal Cancer Clinical Trial page.